Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Coherus BioSciences Inc CHRS

Healthcare Biotechnology
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and... see more

Recent & Breaking News (NDAQ:CHRS)

Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences' Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer

GlobeNewswire September 13, 2021

Coherus Management to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 10, 2021

Coherus BioSciences Announces Upcoming Medical Conference Presentations

GlobeNewswire September 8, 2021

Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

GlobeNewswire September 1, 2021

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire August 27, 2021

Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

GlobeNewswire August 18, 2021

Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

GlobeNewswire August 18, 2021

Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma

GlobeNewswire August 12, 2021

Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress

GlobeNewswire August 5, 2021

Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th

GlobeNewswire July 26, 2021

Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board

GlobeNewswire July 21, 2021

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire July 12, 2021

Coherus and Junshi Biosciences to Host Virtual Investor Event to Discuss Toripalimab and ASCO 2021 Highlights

GlobeNewswire June 4, 2021

Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

GlobeNewswire June 3, 2021

Coherus BioSciences to Present at the Bank of America Health Care Conference

GlobeNewswire May 7, 2021

Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress

GlobeNewswire May 6, 2021

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire April 30, 2021

Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th

GlobeNewswire April 30, 2021

Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting

GlobeNewswire April 29, 2021

Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma

GlobeNewswire April 23, 2021